It is interesting that various mutational profiles of the KRAS mutant lung cancers affect the development of resistance to sotorasib or adagrasib [49] The H95 mutations may confer resistance to adagrasib but does not affect the activity of sotorasib. Here, KRAS is linked to lung carcinoma.